A tumor‐microenvironment‐responsive hydrogel patch was designed to modulate the plasticity of tumor‐initiating cells in triple‐negative breast cancer, which is insensitive to hormone‐ and HER2‐targeting.
6807162 4S8CAYZH items 1 apa default asc 1
Ji, X., Guo, D., Ma, J., Yin, M., Yu, Y., Liu, C., Zhou, Y., Sun, J., Li, Q., Chen, N., Fan, C., & Song, H. (n.d.). Epigenetic Remodeling Hydrogel Patches for Multidrug-Resistant Triple-Negative Breast Cancer. Advanced Materials, n/a(n/a), 2100949. https://doi.org/https://doi.org/10.1002/adma.202100949 Cite
Investigators used breast cancer as an example of the origins of tumor heterogeneity and of tumor cell plasticity, as well as considering interclonal cooperativity and cell plasticity as sources of cancer cell heterogeneity.
[British Journal of Cancer]
Scientists showed that miR-146 was relevant for normal mammary stem cell and mammary cancer stem cell activity.
[Journal of Cell Biology]
6445212 RY4CJLVZ items 1 apa default asc 1
Tordonato, C., Marzi, M. J., Giangreco, G., Freddi, S., Bonetti, P., Tosoni, D., Di Fiore, P. P., & Nicassio, F. (2021). miR-146 connects stem cell identity with metabolism and pharmacological resistance in breast cancer. Journal of Cell Biology, 220(e202009053). https://doi.org/10.1083/jcb.202009053 Cite
Antibody–drug nanoparticles were engineered by synthesizing pure anti-cancer drug nanorods in the core of nanoparticles with a therapeutic monoclonal antibody, Trastuzumab on the surface of NRs for specific targeting and synergistic treatments of human epidermal growth factor receptor 2 positive breast cancer cells.
The authors focus on recent advances in our understanding of doxorubicin induced regulated cardiomyocyte death pathways including autophagy, ferroptosis, necroptosis, pyroptosis and apoptosis.
[Cell Death & Disease]
Researchers identified a clinically relevant signaling nexus mediated by AXL receptor, PYK2 and PKCα and show its impact on stemness in triple-negative breast cancer.
[Life Science Alliance]
Merck announced that the FDA has issued a Complete Response Letter regarding Merck’s supplemental Biologics License Application seeking approval for KEYTRUDA, the company’s anti-PD-1 therapy, for the treatment of patients with high-risk early-stage triple-negative breast cancer, in combination with chemotherapy as neoadjuvant treatment, then continuing as a single agent as adjuvant treatment after surgery.
[Merck (BusinessWire, Inc.)]
6445218 nan items 1 apa default asc 1
Investigators describe a detailed alternative method to cultivate millimeter-scale functional vascularized tissues on a biofabricated platform that enabled facile incorporation of organoid technology.
6445218 8HEGALRI items 1 apa default asc 1
Lai, B. F. L., Lu, R. X. Z., Davenport Huyer, L., Kakinoki, S., Yazbeck, J., Wang, E. Y., Wu, Q., Zhang, B., & Radisic, M. (2021). A well plate–based multiplexed platform for incorporation of organoids into an organ-on-a-chip system with a perfusable vasculature. Nature Protocols, 1–32. https://doi.org/10.1038/s41596-020-00490-1 Cite
To enable cell-type-specific gene manipulation in vitro, scientists establish an organoid system via coculture of endothelial cells (ECs), fibroblasts, and mammary epithelial cells.
6445218 HDBGVWX2 items 1 apa default asc 1
Scientists investigated the role of MCL-1 in clinically relevant breast cancer models and address whether the canonical role of MCL-1 in apoptosis, which can be targeted using BH3-mimetic drugs, is the major function for MCL-1 in breast cancer.
[Cell Death & Differentiation]
6445218 9QRRNG9J items 1 apa default asc 1
Campbell, K. J., Mason, S. M., Winder, M. L., Willemsen, R. B. E., Cloix, C., Lawson, H., Rooney, N., Dhayade, S., Sims, A. H., Blyth, K., & Tait, S. W. G. (2021). Breast cancer dependence on MCL-1 is due to its canonical anti-apoptotic function. Cell Death & Differentiation, 1–12. https://doi.org/10.1038/s41418-021-00773-4 Cite
A single-cell breast cancer mass cytometry panel was optimized to identify cell phenotypes and their oncogenic signaling states in a biobank of patient-derived tumour xenograft models representing the diversity of human breast cancer.
6445218 NSBVKRPU items 1 apa default asc 1
Georgopoulou, D., Callari, M., Rueda, O. M., Shea, A., Martin, A., Giovannetti, A., Qosaj, F., Dariush, A., Chin, S.-F., Carnevalli, L. S., Provenzano, E., Greenwood, W., Lerda, G., Esmaeilishirazifard, E., O’Reilly, M., Serra, V., Bressan, D., Gordon B. Mills, Ali, H. R., … Caldas, C. (2021). Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response. Nature Communications, 12(1), 1998. https://doi.org/10.1038/s41467-021-22303-z Cite